The value of plasma-digoxin assay

Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation.

Journal of pharmacokinetics and biopharmaceutics·2010

Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans.

Clinical pharmacology and therapeutics·1998

A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·1997

Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers.

Anesthesiology·1993

Pharmacokinetic investigations in elderly patients. Clinical and ethical considerations.

Clinical pharmacokinetics·1990

Peroxisome-associated enzymes and serum lipids in tumour-bearing rats treated with peroxisome-proliferating agents.

Biochemical pharmacology·1984

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Evaluation of brexpiprazole as adjunctive therapy in treatment-resistant depression: Real-world data.

Dusunen adam : Bakirkoy Ruh ve Sinir Hastaliklari Hastanesi yayin organi·2026

Unveiling the sumatriptan dose-relief relationship.

European journal of clinical pharmacology·2026

Comparison of Trough-Only and Peak-Trough Concentration Data for the Calculation of Vancomycin Area under the Concentration-Time Curve on Day 2 Using Previous and Updated Population Pharmacokinetic Models.

Biological & pharmaceutical bulletin·2026

Mapping Therapeutic Drug Monitoring Research in Low- and Middle-Income Countries: A Scoping Review (2015-2024).

Therapeutic drug monitoring·2026

Polymeric systems for peptide and protein delivery: design principles, translational barriers, and future research directions.

International journal of pharmaceutics·2026

Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial.

The Lancet. Neurology·2026

Related Experiment Videos

The value of plasma-digoxin assay

Related Concept Videos

Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation.

Pharmacokinetics, cortisol release, and hemodynamics after intravenous and subcutaneous injection of human corticotropin-releasing factor in humans.

A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer.

Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers.

Pharmacokinetic investigations in elderly patients. Clinical and ethical considerations.

Peroxisome-associated enzymes and serum lipids in tumour-bearing rats treated with peroxisome-proliferating agents.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Evaluation of brexpiprazole as adjunctive therapy in treatment-resistant depression: Real-world data.

Unveiling the sumatriptan dose-relief relationship.

Comparison of Trough-Only and Peak-Trough Concentration Data for the Calculation of Vancomycin Area under the Concentration-Time Curve on Day 2 Using Previous and Updated Population Pharmacokinetic Models.

Mapping Therapeutic Drug Monitoring Research in Low- and Middle-Income Countries: A Scoping Review (2015-2024).

Polymeric systems for peptide and protein delivery: design principles, translational barriers, and future research directions.

Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial.

Related Experiment Videos

The value of plasma-digoxin assay

Related Concept Videos

Related Articles